Clinical data of patients and leukemia characteristics
| Patient identification . | Age, mo. . | Immuno-phenotype* . | Thymus tumor . | Bone marrow blasts, % . | Absolute blasts in PB† . | Molecular marker‡ . |
|---|---|---|---|---|---|---|
| 427 | 18 | IV | Yes | 89 | 90 | TCRG Vγ4-Jγ1 |
| 121 | 24 | III | No | 85 | 342 | TAL1 deletionTCRD-LMO2§ |
| FU | 25 | II | Yes | 81 | 131 | TCRG Vγ1-Jγ1 |
| SC | 26 | III | Yes | 48 | 1 | TCRG Vγ1-Jγ1 |
| 254 | 28 | III | Yes | 92 | 328 | TRD Vδ2-Dδ3-Jδ1 |
| 255 | 29 | II | Yes | 73 | 35 | TCRG Vγ8-Jγ1 |
| 270 | 31 | IV | Yes | 88 | 234 | TCRG Vγ8-Jγ1 |
| 115 | 31 | III | Yes | 74 | 15 | TAL1 deletionTCRG Vγ2-Jγ1Notch1 mutation∥ |
| 245 | 38 | IV | No | 58 | 24 | TCRD Vδ1-Dδ3-Jδ1 |
| 476 | 38 | II | na | na | na | TCRG Vγ2-Jγ1 |
| 185 | 40 | IV | No | 95 | 228 | TCRD-LMO2# |
| 338 | 60 | III | Yes | 97 | 71 | TCRD Vδ1-Dδ2-Jδ1 |
| 387 | 77 | III | Yes | 93 | 178 | TCRG Vγ8-Jγ1 |
| 239 | 80 | IV | No | 78 | 25 | TAL1 deletion |
| HA | 90 | III | Yes | 99 | 145 | TCRD Vδ1-Dδ3-Jδ1 |
| 609 | 92 | III | Yes | 70 | 48 | TCRD Vδ1-Dδ2-Dδ3-Jδ1 |
| 364 | 98 | IV | No | 97 | 361 | TCRG Vγ10-Jγ1 |
| 522 | 135 | III | na | na | na | TCRG Vγ9-Jγ1 |
| Patient identification . | Age, mo. . | Immuno-phenotype* . | Thymus tumor . | Bone marrow blasts, % . | Absolute blasts in PB† . | Molecular marker‡ . |
|---|---|---|---|---|---|---|
| 427 | 18 | IV | Yes | 89 | 90 | TCRG Vγ4-Jγ1 |
| 121 | 24 | III | No | 85 | 342 | TAL1 deletionTCRD-LMO2§ |
| FU | 25 | II | Yes | 81 | 131 | TCRG Vγ1-Jγ1 |
| SC | 26 | III | Yes | 48 | 1 | TCRG Vγ1-Jγ1 |
| 254 | 28 | III | Yes | 92 | 328 | TRD Vδ2-Dδ3-Jδ1 |
| 255 | 29 | II | Yes | 73 | 35 | TCRG Vγ8-Jγ1 |
| 270 | 31 | IV | Yes | 88 | 234 | TCRG Vγ8-Jγ1 |
| 115 | 31 | III | Yes | 74 | 15 | TAL1 deletionTCRG Vγ2-Jγ1Notch1 mutation∥ |
| 245 | 38 | IV | No | 58 | 24 | TCRD Vδ1-Dδ3-Jδ1 |
| 476 | 38 | II | na | na | na | TCRG Vγ2-Jγ1 |
| 185 | 40 | IV | No | 95 | 228 | TCRD-LMO2# |
| 338 | 60 | III | Yes | 97 | 71 | TCRD Vδ1-Dδ2-Jδ1 |
| 387 | 77 | III | Yes | 93 | 178 | TCRG Vγ8-Jγ1 |
| 239 | 80 | IV | No | 78 | 25 | TAL1 deletion |
| HA | 90 | III | Yes | 99 | 145 | TCRD Vδ1-Dδ3-Jδ1 |
| 609 | 92 | III | Yes | 70 | 48 | TCRD Vδ1-Dδ2-Dδ3-Jδ1 |
| 364 | 98 | IV | No | 97 | 361 | TCRG Vγ10-Jγ1 |
| 522 | 135 | III | na | na | na | TCRG Vγ9-Jγ1 |
na indicates not available.
II, pro- and pre-T (CD7+cyCD3+CD1−); III, cortical T (CD7+cyCD3+CD1+); IV, mature T (CD7+sCD3+CD1−) T-cell phenotype.
Absolute blast count in peripheral blood × 106/L.
Molecular marker used for tracing the leukemic clone; patients FU and SC were included in an earlier study6 and refer to patients 5 and 4, respectively. Cases with a presumed leukemia initiation before birth and the particular molecular target are italicized.